Leukemia Treatment Drugs Market By Type (Gleevec, Sapacitabine, GA101, Vasaroxine, and Others (Tosedosat, Revlimid, and Bosutinib)), By Application (Hospitals, Research Institutes, and Diagnostic Centres), and By Region-Trends, Analysis and Forecast till 2034

Report Code: PMI326019 | Publish Date: February 2024 | No. of Pages: 170

Global Leukemia Treatment Drugs Market Companies

  • Novartis Pharmaceuticals
  • Merck & Co. Inc.
  • F. Hoffmann-La Roche Ltd.
  • Incyte Corp.
  • Johnson & Johnson
  • AstraZeneca plc
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Pfizer Inc.

Recent News:

  • In November 2022, BeiGene announced that the European Council has approved Brukinsa (zanubrutinib) for the treatment of adult patients with pure or relapsed or refractory (R/R) chronic lymphocytic leukemia (TN). ). October 2022:  US FDA approved quizartinib in combination with standard cytarabine-anthracycline induction chemotherapy and standard cytarabine-based consolidation chemotherapy, and as continuation monotherapy after consolidation, for the treatment of newly diagnosed adult patients with FLT3-ITD-positive AML.
  • In January 2022, the U.S. Food and Drug Administration (FDA) granted the company orphan drug designation for OM-301, manufactured by Oncolyze Inc. manufactured for the treatment of AML.
  • In June 2021, Jazz Pharmaceuticals plc received US FDA approval for Rylaze (Erwinia chrysanthemi asparaginase) for use as a component of a multi-agent chemotherapy regimen to treat ALL or LBL in Children and adults from 1 month of age and older have developed hypersensitivity to E. Asparaginase is derived from E. coli.